Cytomegalovirus After HCT Does Not Protect Against Leukemia Relapse – Cancer Therapy Advisor

March 11, 2016

Cytomegalovirus reactivation after hematopoietic cell transplantation proceeded to be associated along with poorer survival.

Cytomegalovirus (CMV) reactivation after hematopoietic cell transplantation (HCT) proceeded to be associated along with poorer survival, a research published in the diary Blood has actually shown; however, it stayed away from leukemia relapse.¹

Because single-focus studies have actually shown an organization in between very early CMV reactivation prior to day one hundred and low incidence of relapse with acute myeloid leukemia (AML) after allogeneic HCT, researchers sought to substantiate these points out by conducting a retrospective study.

For the study, researchers assessed data from 9469 patients transplanted along with bone marrow or peripheral blood in between 2003 and 2010 that were entailed in the focus with Worldwide Blood and Marrow Transplant study (CIBMTR) Database.

Patients were treated with AML, acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), or myelodysplastic syndrome (MDS).

Researchers discovered that the median time to very first CMV reactivation was 41 days (range, 1 – 362 days).

Results stated that despite diagnosis, CMV reactivation possessed zero preventive influence about hematologic illness relapse.

Further, CMV reactivation was associated along with enhanced non-relapse mortality (RR range amongst illness categories, 1.61 – 1.95; 95% CI, 1.14 – 2.61; P = .0002 to < .0001).

RELATED: Chronic Myelomonocytic Leukemia Q&A along with Opinion Leader Mrinal Patnaik, MD

That boost in non-relapse mortality caused lesser total survival with every one of 4 hematologic malignancies (RR, 1.27; 95% CI, 1.17 – 1.38; P < .0001), every one of (RR; 1.46; 95% CI, 1.25 – 1.71; P < .0001), CML (RR, 1.49; 95% CI, 1.19 – 1.88; P = .0005), and MDS (RR, 1.31; 95% CI, 1.09 – 1.57; P = .003).

Reference

1. Teira P, Battiwalla M, Ramanathan M, et al. very early cytomegalovirus reactivation remains associated along with enhanced transplant related mortality in the latest era: a CIBMTR evaluation [published online ahead of print February 16, 2016]. Blood. doi: 10.1182/blood-2015-11-679639.

Loading links….